ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide.

Bossi AC, De Mori V, Scaranna C, Veronesi G, Lepore G

Diabetes therapy : research, treatment and education of diabetes and related disorders24 Sept 2020Cited by 2 (Europe PMC)

PMID32974879PMCIDPMC7547933DOI10.1007/s13300-020-00929-4PepBankPUB-32974879

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In patients with diabetes, dulaglutide treatment was associated with lower HbA1c than baseline.
In plain wordsIn patients with diabetes, dulaglutide treatment was linked to lower average blood sugar than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n = 1,130
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 or 1.5 mg once weekly · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−10 mmol/mol
12 months
Source sentences
Summary
At 12 months, average HbA1c and average fasting plasma glucose (FPG) were significantly lower compared to baseline levels (- 10 mmol/mol and - 24.9 mg/dL, respectively), as were body weight (- 3.4 kg) and waist circumference (- 3.3 cm) values (all p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of ANDREW (Active Notes on Dulaglutide in the REal World), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24 months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide.
Summary · context
Overall, 1584 subjects (696 women, 888 men) with T2D (mean age [± standard deviation] 61.7 ± 10.2 years; mean T2D duration 9.9 ± 6.9 years) were treated with dulaglutide (0.75 or 1.5 mg once weekly) between April 2016 and December 2019.
Report a problemFND-3297487902
02HumanObservational studyEfficacy outcome
In patients with diabetes, dulaglutide treatment was associated with lower body weight than baseline.
In plain wordsIn patients with diabetes, dulaglutide treatment was linked to lower body weight than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n = 1,130
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 or 1.5 mg once weekly · 12 monthsAs given in this study (human).
Measurements
Body weight change
−3.4 kg
12 months
Source sentences
Summary
At 12 months, average HbA1c and average fasting plasma glucose (FPG) were significantly lower compared to baseline levels (- 10 mmol/mol and - 24.9 mg/dL, respectively), as were body weight (- 3.4 kg) and waist circumference (- 3.3 cm) values (all p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of ANDREW (Active Notes on Dulaglutide in the REal World), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24 months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide.
Summary · context
Overall, 1584 subjects (696 women, 888 men) with T2D (mean age [± standard deviation] 61.7 ± 10.2 years; mean T2D duration 9.9 ± 6.9 years) were treated with dulaglutide (0.75 or 1.5 mg once weekly) between April 2016 and December 2019.
Report a problemFND-3297487904
03HumanObservational studyEfficacy outcome
In diabetes patients completing follow-up, HbA1c stabilized during the second year of dulaglutide treatment after an initial decline.
In plain wordsIn patients with diabetes, average blood sugar remained stable during the second year of dulaglutide treatment after an initial decline.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c stabilization
Study
n = 270
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 or 1.5 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
Among subjects that completed 24 months of follow-up (n = 270), the rapid decline in HbA1c and FPG values in the first 12 months was followed by stabilization in the following 12 months (p value for 12-24 months trend: 0.4 and 0.6, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of ANDREW (Active Notes on Dulaglutide in the REal World), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24 months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide.
Summary · context
Overall, 1584 subjects (696 women, 888 men) with T2D (mean age [± standard deviation] 61.7 ± 10.2 years; mean T2D duration 9.9 ± 6.9 years) were treated with dulaglutide (0.75 or 1.5 mg once weekly) between April 2016 and December 2019.
Report a problemFND-3297487906
04HumanObservational studyOther
In patients with diabetes receiving dulaglutide, 170 interrupted treatment before the 12-month endpoint.
In plain wordsAmong patients with diabetes receiving dulaglutide, 170 interrupted treatment before the 12-month endpoint.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTreatment interruption
Study
n = 1,584
Outcome group
Treatment adherence and retention · Whole body
Studied dose
0.75 or 1.5 mg once weekly · 12 monthsAs given in this study (human).
Measurements
Treatment interruptions
170 patients
before 12 months
Source sentences
Summary
A total of 1130 patients completed 12 months of follow-up, while 170 patients interrupted treatment before the 12-month endpoint.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of ANDREW (Active Notes on Dulaglutide in the REal World), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24 months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide.
Summary · context
Overall, 1584 subjects (696 women, 888 men) with T2D (mean age [± standard deviation] 61.7 ± 10.2 years; mean T2D duration 9.9 ± 6.9 years) were treated with dulaglutide (0.75 or 1.5 mg once weekly) between April 2016 and December 2019.
Report a problemFND-3297487901
05HumanObservational studyEfficacy outcome
In patients with diabetes, dulaglutide treatment was associated with lower fasting plasma glucose than baseline.
In plain wordsIn patients with diabetes, dulaglutide treatment was linked to lower fasting blood sugar than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose change
Study
n = 1,130
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 or 1.5 mg once weekly · 12 monthsAs given in this study (human).
Measurements
FPG change
−24.9 mg/dL
12 months
Source sentences
Summary
At 12 months, average HbA1c and average fasting plasma glucose (FPG) were significantly lower compared to baseline levels (- 10 mmol/mol and - 24.9 mg/dL, respectively), as were body weight (- 3.4 kg) and waist circumference (- 3.3 cm) values (all p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of ANDREW (Active Notes on Dulaglutide in the REal World), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24 months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide.
Summary · context
Overall, 1584 subjects (696 women, 888 men) with T2D (mean age [± standard deviation] 61.7 ± 10.2 years; mean T2D duration 9.9 ± 6.9 years) were treated with dulaglutide (0.75 or 1.5 mg once weekly) between April 2016 and December 2019.
Report a problemFND-3297487903
06HumanObservational studyEfficacy outcome
In patients with diabetes, dulaglutide treatment was associated with lower waist circumference than baseline.
In plain wordsIn patients with diabetes, dulaglutide treatment was linked to a smaller waist than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWaist circumference change
Study
n = 1,130
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 or 1.5 mg once weekly · 12 monthsAs given in this study (human).
Measurements
Waist circumference change
−3.3 cm
12 months
Source sentences
Summary
At 12 months, average HbA1c and average fasting plasma glucose (FPG) were significantly lower compared to baseline levels (- 10 mmol/mol and - 24.9 mg/dL, respectively), as were body weight (- 3.4 kg) and waist circumference (- 3.3 cm) values (all p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of ANDREW (Active Notes on Dulaglutide in the REal World), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24 months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide.
Summary · context
Overall, 1584 subjects (696 women, 888 men) with T2D (mean age [± standard deviation] 61.7 ± 10.2 years; mean T2D duration 9.9 ± 6.9 years) were treated with dulaglutide (0.75 or 1.5 mg once weekly) between April 2016 and December 2019.
Report a problemFND-3297487905
07HumanObservational studyEfficacy outcome
In diabetes patients completing follow-up, fasting glucose stabilized during the second year of dulaglutide treatment after an initial decline.
In plain wordsIn patients with diabetes, fasting blood sugar remained stable during the second year of dulaglutide treatment after an initial decline.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeFasting plasma glucose stabilization
Study
n = 270
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 or 1.5 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
Among subjects that completed 24 months of follow-up (n = 270), the rapid decline in HbA1c and FPG values in the first 12 months was followed by stabilization in the following 12 months (p value for 12-24 months trend: 0.4 and 0.6, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of ANDREW (Active Notes on Dulaglutide in the REal World), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24 months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide.
Summary · context
Overall, 1584 subjects (696 women, 888 men) with T2D (mean age [± standard deviation] 61.7 ± 10.2 years; mean T2D duration 9.9 ± 6.9 years) were treated with dulaglutide (0.75 or 1.5 mg once weekly) between April 2016 and December 2019.
Report a problemFND-3297487907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.